Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development. New ...
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development. New ...
Final participant randomized to complete enrollment in Phase 1 clinical trial assessing safety of investigational gene therapy AB-1005 delivered to the putamen in patients with multiple system atrophy ...
A leading neurologist involved in the clinical development of Alterity Therapeutic’s lead compound ATH434 believes it could ...
A major UK study has revealed that the early warning signs of multiple sclerosis (MS) - including pain, mood changes, and neurological symptoms such as numbness and tingling – may appear years before ...
Sara's Ride honor's a brave Bear Valley woman's fight with rare disorder, raises funds and awareness
More than 40 people gathered at the Bear Valley Springs Equestrian Center Saturday to honor the memory of Sara Nilson, who ...
The human body requires protein as one of its fundamental nutritional elements, and it is known as the 'building block of the ...
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first European participants have been randomized in ...
Based on prior investigator-initiated trials, the SynuSight Biotech developed technology, showed the potential to become the world's first α-syn-targeted PET tracer for Parkinson's disease (PD), ...
In recent years, the U.S. Food and Drug Administration (FDA) has approved a wave of new therapies, including gene therapies, ...
Despite a trial failure in Parkinson’s disease, Novartis is having a second bite of the alpha-synuclein cherry with Arrowhead’s drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback